Emergers publishes an updated analysis on Prolight Diagnostics, reaffirming a justified value of 1.1-1.2 SEK per share

Read the full article here: https://www.emergers.se/prolight_e/

For further information, please contact:
Ulf Bladin, CEO
E-mail: ub@prolightdx.com
Phone: +46 73 582 39 87
Company website: www.prolightdx.com

About Us
Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.
We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.
 
The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments
Emergers publishes an updated analysis on Prolight Diagnostics, reaffirming a justified value of 1.1-1.2 SEK per share

Emergers publishes an updated analysis on Prolight Diagnostics, reaffirming a justified value of 1.1-1.2 SEK per share
Back

Subscribe